ELIQUENT Life Sciences Joins €13 Million Horizon Europe Consortium to Advance Regulatory Development of Novel Osteoarthritis Therapy
The consortium also aims to contribute to more standardized approaches, robust analytical and potency-assessment methods, and a clearer regulatory pathway for future secretome-based medicines. Joana Correia, PhD, Co-Founder and Chief Executive Officer of Exogenus Therapeutics, said in the consortium announcement:…